NKGN רווח למניה בשנים עשר החודשים האחרונים NKGen Biotech Corp

NKGen Biotech, Inc. (NKGN) focuses on developing cell-based therapies using NK cells to combat Alzheimer's disease. However, the costs of clinical trials in the absence of sales are depleting cash reserves. The 12-month rolling EPS chart provided by GURU.Markets illustrates the financial dynamics, where the -2.28 level captures the current state. The company's prospects are expanding through the development of cancer therapies, merging oncology and neurology.

Reducing investment risks requires an analysis of the business's actual earnings per common share. For NKGen Biotech, Inc. (NKGN), this parameter is critical, as the commercialization of NK-cell therapy for Alzheimer's disease has not yet generated a stable cash flow. The 12-month net income per share history aggregates the final financial results of four quarters. This metric strips the total profit of the impact of securities issuance. The indicator's trend allows for an objective assessment of the cost of capital.